Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | PAK4 | O96013 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30026496 | 1.00 | MAP4K4 (0.38) | MAP4K4EGLN1MPOGRM5KDM4E | |
| Methyl Phosphonate SCHEMBL28467022 | 0.93 | EGLN1 (0.37) | MAP4K4EGLN1MPOKDM4EMEN1 | |
| SCHEMBL30026030 | 0.92 | CDC7 (0.33) | MAP4K4MPOKDM4EMEN1ALDH1A1 | |
| SCHEMBL21054751 | 0.92 | CDC7 (0.33) | MAP4K4MPOKDM4EMEN1ALDH1A1 | |
| SCHEMBL510467 | 0.90 | MEN1 (0.42) | MAP4K4EGLN1MPOKDM4EMEN1 | |
| SCHEMBL30026560 | 0.90 | MEN1 (0.42) | MAP4K4EGLN1MPOKDM4EMEN1 | |
| SCHEMBL30026275 | 0.89 | MPO (0.42) | MAP4K4MPOMEN1ALDH1A1KMT2A | |
| SCHEMBL510412 | 0.89 | MPO (0.42) | MAP4K4MPOMEN1ALDH1A1KMT2A | |
| SCHEMBL21099230 | 0.89 | MAP4K4 (0.38) | MAP4K4EGLN1MPOKDM4EMEN1 | |
| SCHEMBL30025434 | 0.89 | MAP4K4 (0.38) | MAP4K4EGLN1MPOKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065881-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | US | claimed |
| US-20210163461-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2021-06-03 | — | — | US | claimed |
| WO-2020247804-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2020-12-10 | — | — | WO | claimed |
| EP-3720438-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | Amplyx Pharmaceuticals, Inc. (US) | 2020-10-14 | — | — | EP | claimed |
| CN-111698989-A | Heterocyclic substituted pyridine derivative antifungal agent | 安普利克斯制药公司 | 2020-09-22 | — | — | CN | claimed |
| WO-2019113542-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | claimed |
| US-20250101012-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2025-03-27 | — | — | US | disclosed |
| US-12139479-B2 | Heterocycle substituted pyridine derivative antifungal agents | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2024-11-12 | — | — | US | disclosed |
| EP-3720438-B1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3720438-B1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS INC (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-111698989-B | Heterocyclic substituted pyridine derivatives as antifungal agents | 安普利克斯制药公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20230065881-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230065881-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | AMPLYX PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1944303-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101012-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | MAP4K4 825/4885EGLN1 121/4885MPO 1597/4885 |
| US-20210163461-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | MAP4K4 825/4885EGLN1 121/4885MPO 1597/4885 |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | ERG28, H1-2, H1-3 | MAP4K4 630/4885EGLN1 105/4885MPO 1859/4885 |
| US-20230065881-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | MAP4K4 825/4885EGLN1 121/4885MPO 1597/4885 |
| US-12139479-B2 | Heterocycle substituted pyridine derivative antifungal agents | ERG28, DPM1, CYP51A1 | MAP4K4 825/4885EGLN1 121/4885MPO 1597/4885 |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | GPI, ERG28, MAN2A1 | MAP4K4 2997/4885EGLN1 344/4885MPO 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.